The DOI matches its Crossref record; 227 of the 227 references it cites were found in a registry or an index.
Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials
Open accessAbstract
CRISPR reveals that many cancer drug targets are dispensable for cell proliferation and identifies CDK11 as the target of one mischaracterized agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Liu, K., Gao, H. Y., Wang, Q., Wang, L., Zhang, B., Han, Z., Chen, X., Han, M., & Gao, M. (2018) · Cancer Science · doi:10.1111/cas.13575 · Cited by 80
RetractedBalliu, M., Guandalini, L., Romanelli, M. N., D’Amico, M., & Paoletti, F. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12345 · Cited by 31
RetractedChai, Y., Xue, H., Wu, Y., Du, X., Zhang, Z., Zhang, Y., Zhang, L., Zhang, S., Zhang, Z., & Xue, Z. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6020 · Cited by 24
RetractedExpression and function of PIM kinases in osteosarcoma
Mou, S., Wang, G., Ding, D., Yu, D., Pei, Y., Teng, S., & Fu, Q. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3708 · Cited by 15
RetractedGene Expression Omnibus: NCBI gene expression and hybridization array data repository
Edgar, R. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.207 · Cited by 13,288
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation
Gilbert, L. A., Horlbeck, M. A., Adamson, B., Villalta, J. E., Chen, Y., Whitehead, E. H., Guimaraes, C., Panning, B., Ploegh, H. L., Bassik, M. C., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.029 · Cited by 2,728
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
HDAC6 is a microtubule-associated deacetylase
Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.-F., & Yao, T.-P. (2002) · Nature · doi:10.1038/417455a · Cited by 2,403 · cited 1×
“For instance, HDAC6 is capable of deacetylating microtubules (26), and HDAC6 inhibition has been reported to render cells vulnerable to drugs that interfere with microtubule dynamics (27).”
BackgroundExpression profiling reveals off-target gene regulation by RNAi
Jackson, A. L., Bartz, S. R., Schelter, J., Kobayashi, S. V., Burchard, J., Mao, M., Li, B., Cavet, G., & Linsley, P. S. (2003) · Nature Biotechnology · doi:10.1038/nbt831 · Cited by 2,370
COSMIC: exploring the world's knowledge of somatic mutations in human cancer
Forbes, S. A., Beare, D., Gunasekaran, P., Leung, K., Bindal, N., Boutselakis, H., Ding, M., Bamford, S., Cole, C., Ward, S., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1075 · Cited by 2,283
Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast
Heitman, J., Movva, N. R., & Hall, M. N. (1991) · Science · doi:10.1126/science.1715094 · Cited by 2,006
Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
Seto, E., & Yoshida, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018713 · Cited by 1,989
Meyers, R. M., Bryan, J. G., McFarland, J. M., Weir, B. A., Sizemore, A. E., Xu, H., Dharia, N. V., Montgomery, P. G., Cowley, G. S., Pantel, S., et al. (2017) · Nature Genetics · doi:10.1038/ng.3984 · Cited by 1,952
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
Estimation of clinical trial success rates and related parameters
Wong, C. H., Siah, K. W., & Lo, A. W. (2019) · Biostatistics · doi:10.1093/biostatistics/kxx069 · Cited by 1,585
Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., & Snyder, S. H. (1994) · Cell · doi:10.1016/0092-8674(94)90570-3 · Cited by 1,509
BLAST: a more efficient report with usability improvements
Boratyn, G. M., Camacho, C., Cooper, P. S., Coulouris, G., Fong, A., Ma, N., Madden, T. L., Matten, W. T., McGinnis, S. D., Merezhuk, Y., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt282 · Cited by 1,369
Genetic compensation triggered by mutant mRNA degradation
El-Brolosy, M. A., Kontarakis, Z., Rossi, A., Kuenne, C., Günther, S., Fukuda, N., Kikhi, K., Boezio, G. L. M., Takacs, C. M., Lai, S.-L., et al. (2019) · Nature · doi:10.1038/s41586-019-1064-z · Cited by 1,028
Kinase inhibitors: the road ahead
Ferguson, F. M., & Gray, N. S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.21 · Cited by 1,009
Genetic and transcriptional evolution alters cancer cell line drug response
Ben-David, U., Siranosian, B., Ha, G., Tang, H., Oren, Y., Hinohara, K., Strathdee, C. A., Dempster, J., Lyons, N. J., Burns, R., et al. (2018) · Nature · doi:10.1038/s41586-018-0409-3 · Cited by 931 · cited 1×
“Assessing putative cancer dependencies in whole-genome CRISPR and RNAi screens Cell lines can exhibit interlaboratory variability that affects their response to different genetic and chemical perturbations (24).”
Background3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets
Birmingham, A., Anderson, E. M., Reynolds, A., Ilsley-Tyree, D., Leake, D., Fedorov, Y., Baskerville, S., Maksimova, E., Robinson, K., Karpilow, J., et al. (2006) · Nature Methods · doi:10.1038/nmeth854 · Cited by 920
Horlbeck, M. A., Gilbert, L. A., Villalta, J. E., Adamson, B., Pak, R. A., Chen, Y., Fields, A. P., Park, C. Y., Corn, J. E., Kampmann, M., et al. (2016) · eLife · doi:10.7554/elife.19760 · Cited by 894
The target landscape of clinical kinase drugs
Klaeger, S., Heinzlmeir, S., Wilhelm, M., Polzer, H., Vick, B., Koenig, P.-A., Reinecke, M., Ruprecht, B., Petzoldt, S., Meng, C., et al. (2017) · Science · doi:10.1126/science.aan4368 · Cited by 854 · cited 1×
“DISCUSSION It is generally known that small molecules can exhibit off-target effects that may confound the design of specific chemical inhibitors (46).”
BackgroundDiscovery of cancer drug targets by CRISPR-Cas9 screening of protein domains
Shi, J., Wang, E., Milazzo, J. P., Wang, Z., Kinney, J. B., & Vakoc, C. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3235 · Cited by 761
Phase II and phase III failures: 2013–2015
Harrison, R. K. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.184 · Cited by 636
Santo, L., Hideshima, T., Kung, A. L., Tseng, J.-C., Tamang, D., Yang, M., Jarpe, M., van Duzer, J. H., Mazitschek, R., Ogier, W. C., et al. (2012) · Blood · doi:10.1182/blood-2011-10-387365 · Cited by 616
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
Rizos, H., Menzies, A. M., Pupo, G. M., Carlino, M. S., Fung, C., Hyman, J., Haydu, L. E., Mijatov, B., Becker, T. M., Boyd, S. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3122 · Cited by 547
Safe harbours for the integration of new DNA in the human genome
Sadelain, M., Papapetrou, E. P., & Bushman, F. D. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3179 · Cited by 441
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
Sharma, S. V., & Settleman, J. (2007) · Genes & Development · doi:10.1101/gad.1609907 · Cited by 441
CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes
Evers, B., Jastrzebski, K., Heijmans, J. P. M., Grernrum, W., Beijersbergen, R. L., & Bernards, R. (2016) · Nature Biotechnology · doi:10.1038/nbt.3536 · Cited by 417
McFarland, J. M., Ho, Z. V., Kugener, G., Dempster, J. M., Montgomery, P. G., Bryan, J. G., Krill-Burger, J. M., Green, T. M., Vazquez, F., Boehm, J. S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06916-5 · Cited by 403
Inhibitors of cyclin-dependent kinases as cancer therapeutics.
Whittaker, S. R., Mallinger, A., Workman, P., & Clarke, P. A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.008 · Cited by 384
Drugs as P-glycoprotein substrates, inhibitors, and inducers
Kim, R. B. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001389 · Cited by 382
Force, T., & Kolaja, K. L. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3252 · Cited by 363
Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy
Putt, K. S., Chen, G. W., Pearson, J. M., Sandhorst, J. S., Hoagland, M. S., Kwon, J.-T., Hwang, S.-K., Jin, H., Churchwell, M. I., Cho, M.-H., et al. (2006) · Nature Chemical Biology · doi:10.1038/nchembio814 · Cited by 354
Murray, B. W., Guo, C., Piraino, J., Westwick, J. K., Zhang, C., Lamerdin, J., Dagostino, E., Knighton, D., Loi, C.-M., Zager, M., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911863107 · Cited by 325
Yang, X. H., Sladek, T. L., Liu, X., Butler, B. R., Froelich, C. J., & Thor, A. D. (2001) · PubMed · Cited by 299
Midostaurin approved for FLT3-mutated AML
Levis, M. (2017) · Blood · doi:10.1182/blood-2017-05-782292 · Cited by 291
Requirement for PAK4 in the Anchorage-independent Growth of Human Cancer Cell Lines
Callow, M. G., Clairvoyant, F., Zhu, S., Schryver, B., Whyte, D. B., Bischoff, J. R., Jallal, B., & Smeal, T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m105732200 · Cited by 288
Kim, C., Sano, Y., Todorova, K., Carlson, B. A., Arpa, L., Celada, A., Lawrence, T., Otsu, K., Brissette, J. L., Arthur, J. S. C., et al. (2008) · Nature Immunology · doi:10.1038/ni.1640 · Cited by 265
The Cytoplasmic Deacetylase HDAC6 Is Required for Efficient Oncogenic Tumorigenesis
Lee, Y.-S., Lim, K.-H., Guo, X., Kawaguchi, Y., Gao, Y., Barrientos, T., Ordentlich, P., Wang, X.-F., Counter, C. M., & Yao, T.-P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0188 · Cited by 260
Vogl, D. T., Raje, N., Jagannath, S., Richardson, P., Hari, P., Orlowski, R., Supko, J. G., Tamang, D., Yang, M., Jones, S. S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2526 · Cited by 253
Brasó-Maristany, F., Filosto, S., Catchpole, S., Marlow, R., Quist, J., Francesch-Domenech, E., Plumb, D. A., Zakka, L., Gazinska, P., Liccardi, G., et al. (2016) · Nature Medicine · doi:10.1038/nm.4198 · Cited by 247
ARID1A-mutated ovarian cancers depend on HDAC6 activity
Bitler, B. G., Wu, S., Park, P. H., Hai, Y., Aird, K. M., Wang, Y., Zhai, Y., Kossenkov, A. V., Vara-Ailor, A., Rauscher III, F. J., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3582 · Cited by 232
Killing cells by targeting mitosis
Manchado, E., Guillamot, M., & Malumbres, M. (2012) · Cell Death & Differentiation · doi:10.1038/cdd.2011.197 · Cited by 228
HDAC6 Inhibition Restores Ciliary Expression and Decreases Tumor Growth
Gradilone, S. A., Radtke, B. N., Bogert, P. S., Huang, B. Q., Gajdos, G. B., & LaRusso, N. F. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2938 · Cited by 224
Therapeutic opportunities for manipulating TReg cells in autoimmunity and cancer
von Boehmer, H., & Daniel, C. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3683 · Cited by 220
Bergman, J. A., Woan, K., Perez-Villarroel, P., Villagra, A., Sotomayor, E. M., & Kozikowski, A. P. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301098e · Cited by 195
Smith, I., Greenside, P. G., Natoli, T., Lahr, D. L., Wadden, D., Tirosh, I., Narayan, R., Root, D. E., Golub, T. R., Subramanian, A., et al. (2017) · PLOS Biology · doi:10.1371/journal.pbio.2003213 · Cited by 194
Park, J.-H., Lin, M.-L., Nishidate, T., Nakamura, Y., & Katagiri, T. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1601 · Cited by 187
Regulation of CD133 by HDAC6 Promotes β-Catenin Signaling to Suppress Cancer Cell Differentiation
Mak, A. B., Nixon, A. M. L., Kittanakom, S., Stewart, J. M., Chen, G. I., Curak, J., Gingras, A.-C., Mazitschek, R., Neel, B. G., Stagljar, I., et al. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.09.016 · Cited by 183
Siu, M. K. Y., Chan, H. Y., Kong, D. S. H., Wong, E. S. Y., Wong, O. G. W., Ngan, H. Y. S., Tam, K. F., Zhang, H., Li, Z., Chan, Q. K. Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907481107 · Cited by 177
Ins and Outs of Kinase DFG Motifs
Treiber, D. K., & Shah, N. P. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.06.001 · Cited by 173
PAC-1 Activates Procaspase-3 in Vitro through Relief of Zinc-Mediated Inhibition
Peterson, Q. P., Goode, D. R., West, D. C., Ramsey, K. N., Lee, J. J. Y., & Hergenrother, P. J. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.03.003 · Cited by 170
Essential role of HDAC6 in the regulation of PD‐L1 in melanoma
Lienlaf, M., Perez-Villarroel, P., Knox, T., Pabon, M., Sahakian, E., Powers, J., Woan, K. V., Lee, C., Cheng, F., Deng, S., et al. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2015.12.012 · Cited by 170
Horiuchi, D., Camarda, R., Zhou, A. Y., Yau, C., Momcilovic, O., Balakrishnan, S., Corella, A. N., Eyob, H., Kessenbrock, K., Lawson, D. A., et al. (2016) · Nature Medicine · doi:10.1038/nm.4213 · Cited by 170
Small-Molecule Activators of a Proenzyme
Wolan, D. W., Zorn, J. A., Gray, D. C., & Wells, J. A. (2009) · Science · doi:10.1126/science.1177585 · Cited by 169
PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas
Lu, H., Liu, S., Zhang, G., Wu, B., Zhu, Y., Frederick, D. T., Hu, Y., Zhong, W., Randell, S., Sadek, N., et al. (2017) · Nature · doi:10.1038/nature24040 · Cited by 169
Gupta, J., del Barco Barrantes, I., Igea, A., Sakellariou, S., Pateras, I. S., Gorgoulis, V. G., & Nebreda, A. R. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.019 · Cited by 166
Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma
Cosset, É., Ilmjärv, S., Dutoit, V., Elliott, K., von Schalscha, T., Camargo, M. F., Reiss, A., Moroishi, T., Seguin, L., Gomez, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.016 · Cited by 166
Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer
Kimmelman, A. C., Hezel, A. F., Aguirre, A. J., Zheng, H., Paik, J.-H., Ying, H., Chu, G. C., Zhang, J. X., Sahin, E., Yeo, G., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809966105 · Cited by 163
LKB1, Salt-Inducible Kinases, and MEF2C Are Linked Dependencies in Acute Myeloid Leukemia
Tarumoto, Y., Lu, B., Somerville, T. D. D., Huang, Y., Milazzo, J. P., Wu, X., Klingbeil, O., Demerdash, O. E., Shi, J., & Vakoc, C. R. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.02.011 · Cited by 163
Inhibition of the p38 Kinase Suppresses the Proliferation of Human ER-Negative Breast Cancer Cells
Chen, L., Mayer, J. A., Krisko, T. I., Speers, C. W., Wang, T., Hilsenbeck, S. G., & Brown, P. H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1636 · Cited by 161
Ayllón, V., & O’Connor, R. (2006) · Oncogene · doi:10.1038/sj.onc.1210142 · Cited by 157
P-glycoprotein as multidrug transporter: a critical review of current multidrug resistant cell lines
Nielsen, D. L., & Skovsgaard, T. (1992) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/0925-4439(92)90131-6 · Cited by 155
Lin, A., Giuliano, C. J., Sayles, N. M., & Sheltzer, J. M. (2017) · eLife · doi:10.7554/elife.24179 · Cited by 155
Self-citationHideshima, T., Qi, J., Paranal, R. M., Tang, W., Greenberg, E. F., West, N. H., Colling, M. E., Estiu, G. L., Mazitschek, R., Perry, J. A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608067113 · Cited by 151
Glaab, W. (1997) · Carcinogenesis · doi:10.1093/carcin/18.1.1 · Cited by 150
Zhu, F., Zykova, T. A., Kang, B. S., Wang, Z., Ebeling, M. C., Abe, Y., Ma, W., Bode, A. M., & Dong, Z. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.048 · Cited by 150
Woan, K. V., Lienlaf, M., Perez-Villarroel, P., Lee, C., Cheng, F., Knox, T. J., Woods, D. M., Barrios, K., Powers, J. J., Sahakian, E., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.04.002 · Cited by 149
Leelahavanichkul, K., Amornphimoltham, P., Molinolo, A., Basile, J. R., Koontongkaew, S., & Gutkind, J. S. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.10.003 · Cited by 145
HDAC6 and SIRT2 Regulate the Acetylation State and Oncogenic Activity of Mutant K-RAS
Yang, M. H., Laurent, G., Bause, A. S., Spang, R., German, N. J., Haigis, M. C., & Haigis, K. M. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0040-t · Cited by 144
Matsuo, Y., Park, J.-H., Miyamoto, T., Yamamoto, S., Hisada, S., Alachkar, H., & Nakamura, Y. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3010277 · Cited by 143
Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models
Huang, P., Almeciga-Pinto, I., Jarpe, M. B., van Duzer, J. H., Mazitschek, R., Yang, M., Jones, S. S., & Quayle, S. N. (2016) · Oncotarget · doi:10.18632/oncotarget.13738 · Cited by 143
Development of a histone deacetylase 6 inhibitor and its biological effects
Lee, J.-H., Mahendran, A., Yao, Y., Ngo, L., Venta-Perez, G., Choy, M. L., Kim, N., Ham, W.-S., Breslow, R., & Marks, P. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313893110 · Cited by 141
Cerbini, T. A., Funahashi, R., Luo, Y., Liu, C., Park, K., Rao, M. S., Malik, N., & Zou, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116032 · Cited by 141
Mitosis as an anti-cancer target
Janssen, A., & Medema, R. H. (2011) · Oncogene · doi:10.1038/onc.2011.30 · Cited by 137
Comes, F., Matrone, A., Stella, A., Nico, B., Susca, F. C., Bagnulo, R., Ingravallo, G., Modica, S., Sasso, G. L., Moschetta, A., et al. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402076 · Cited by 133
Generating Single Cell–Derived Knockout Clones in Mammalian Cells with CRISPR/Cas9
Giuliano, C. J., Lin, A., Girish, V., & Sheltzer, J. M. (2019) · Current Protocols in Molecular Biology · doi:10.1002/cpmb.100 · Cited by 130
Self-citationMolecular Basis of Drug Resistance in Aurora Kinases
Girdler, F., Sessa, F., Patercoli, S., Villa, F., Musacchio, A., & Taylor, S. S. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.04.013 · Cited by 128
Hu, F., Gartenhaus, R. B., Eichberg, D. G., Liu, Z., Fang, H.-B., & Rapoport, A. P. (2010) · Oncogene · doi:10.1038/onc.2010.275 · Cited by 128
Ai, J., Wang, Y., Dar, J. A., Liu, J., Liu, L., Nelson, J. B., & Wang, Z. (2009) · Molecular Endocrinology · doi:10.1210/me.2009-0188 · Cited by 126
The proto-oncogene Pim-1 is a target of miR-33a
Thomas, M., Lange‐Grünweller, K., Weirauch, U., Gutsch, D., Aigner, A. M., Grünweller, A., & Hartmann, R. K. (2011) · Oncogene · doi:10.1038/onc.2011.278 · Cited by 125
Herrero‐Martín, D., Osuna, D., Ordóñez, J. L., Sevillano, V., Martins, A. S., Mackintosh, C., Campos, M., Madoz‐Gúrpide, J., Otero-Motta, A. P., Caballero, G., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605104 · Cited by 124
Tyagi, N., Bhardwaj, A., Singh, A. P., McClellan, S. B., Carter, J. E., & Singh, S. (2014) · Oncotarget · doi:10.18632/oncotarget.2398 · Cited by 124
HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma
Wang, Z., Hu, P., Tang, F., Lian, H., Chen, X., Zhang, Y., He, X., Liu, W., & Xie, C. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.06.001 · Cited by 123
Campbell, R. M., Anderson, B. D., Brooks, N. A., Brooks, H. B., Chan, E. M., De Dios, A., Gilmour, R., Graff, J. R., Jambrina, E., Mader, M., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0513 · Cited by 121
Sloane, D. A., Trikić, M. Z., Chu, M. L.-H., Lamers, M., Mason, C., Müller, I., Savory, W. J., Williams, D. H., & Eyers, P. A. (2010) · ACS Chemical Biology · doi:10.1021/cb100053q · Cited by 120
Chiacchiera, F., Matrone, A., Ferrari, E., Ingravallo, G., Lo Sasso, G., Murzilli, S., Petruzzelli, M., Salvatore, L., Moschetta, A., & Simone, C. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2009.36 · Cited by 117
Neggers, J. E., Kwanten, B., Dierckx, T., Noguchi, H., Voet, A. R. D., Bral, L., Minner, K., Massant, B., Kint, N., Delforge, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02349-8 · Cited by 117
Yang, Z., Wang, T., Wang, F., Niu, T., Liu, Z., Chen, X. L., Long, C., Tang, M., Cao, D., Wang, X., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01342 · Cited by 114
Cánovas, B., Igea, A., Sartori, A. A., Gomis, R. R., Paull, T. T., Isoda, M., Perez‐Montoyo, H., Serra, V., González‐Suárez, E., Stracker, T. H., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.010 · Cited by 114
A Novel Class of Small Molecule Inhibitors of HDAC6
Inks, E. S., Josey, B. J., Jesinkey, S. R., & Chou, C. J. (2011) · ACS Chemical Biology · doi:10.1021/cb200134p · Cited by 112
Zhang, J., Wang, J., Guo, Q., Wang, Y., Zhou, Y. Y., Peng, H., Cheng, M., Zhao, D., & Li, F. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.11.007 · Cited by 109
HDAC6 Deacetylates Ku70 and Regulates Ku70-Bax Binding in Neuroblastoma
Subramanian, C., Jarzembowski, J. A., Opipari, A. W., Castle, V. P., & Kwok, R. P. S. (2011) · Neoplasia · doi:10.1593/neo.11558 · Cited by 108
Ye, C., Zhang, C., Huang, H., Yang, B., Xiao, G., Kong, D.-P., Tian, Q., Song, Q., Song, X., Tan, H., et al. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000492009 · Cited by 108
A limited number of double-strand DNA breaks is sufficient to delay cell cycle progression
van den Berg, J., Manjón, A. G., Kielbassa-Elkadi, K., Feringa, F. M., Freire, R., & Medema, R. H. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky786 · Cited by 108
p21-Activated kinase 4 promotes prostate cancer progression through CREB
Park, M.-H., Lee, H.-S., Lee, C., You, S.-T., Kim, D.-J., Park, B.-H., Kang, M., Heo, W. D., Shin, E.-Y., Schwartz, M. A., et al. (2012) · Oncogene · doi:10.1038/onc.2012.255 · Cited by 105
Yang, J., Yuan, D., Xing, T., Su, H.-L., Zhang, S., Wen, J., Bai, Q., & Dang, D. (2016) · Journal of Ginseng Research · doi:10.1016/j.jgr.2016.03.007 · Cited by 104
Joel, M., Mughal, A. A., Grieg, Z., Murrell, W. G., Palmero, S., Mikkelsen, B., Fjerdingstad, H. B., Sandberg, C. J., Behnan, J., Glover, J. C., et al. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0398-x · Cited by 102
Aboukameel, A., Muqbil, I., Senapedis, W. T., Baloglu, E., Landesman, Y., Shacham, S., Kauffman, M. G., Philip, P. A., Mohammad, R. M., & Azmi, A. S. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0205 · Cited by 102
MELK expression correlates with tumor mitotic activity but is not required for cancer growth
Giuliano, C. J., Lin, A., Smith, J. C., Palladino, A. C., & Sheltzer, J. M. (2018) · eLife · doi:10.7554/elife.32838 · Cited by 102
Self-citationTabusa, H., Brooks, T., & Massey, A. J. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0466 · Cited by 101
HDAC6 promotes hepatocellular carcinoma progression by inhibiting P53 transcriptional activity
Ding, G., Liu, H., Huang, Q., Liang, H., Ding, Z.-H., Liao, Z., & Huang, G. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.02.001 · Cited by 100
Amengual, J. E., Johannet, P. M., Lombardo, M., Zullo, K. M., Hoehn, D., Bhagat, G., Scotto, L., Jirau-Serrano, X., Radeski, D., Heinen, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3068 · Cited by 100
Yang, X., Zheng, F., Xing, H., Gao, Q., Wei, W., Lu, Y., Wang, S., Zhou, J., Hu, W., & Ma, D. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0556-9 · Cited by 100
Depetter, Y., Geurs, S., Vreese, R. D., Goethals, S., Vandoorn, E., Laevens, A., Steenbrugge, J., Meyer, E., Tullio, P. D., Bracke, M., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32169 · Cited by 99
Hypoxia-Mediated Up-Regulation of Pim-1 Contributes to Solid Tumor Formation
Chen, J., Kobayashi, M., Darmanin, S., 高橋, 義., Gully, C., Zhao, R., Kondo, S., Wang, H., Wang, H., Yeung, S. J., et al. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080972 · Cited by 98
CDK11p58 is required for the maintenance of sister chromatid cohesion
Hu, D., Valentine, M. B., Kidd, V. J., & Lahti, J. M. (2007) · Journal of Cell Science · doi:10.1242/jcs.007963 · Cited by 98
DNA sequencing and CRISPR-Cas9 gene editing for target validation in mammalian cells
Smurnyy, Y. D., Cai, M., Wu, H., McWhinnie, E. A., Tallarico, J. A., Yang, Y., & Feng, Y. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1550 · Cited by 98
Functional Role and Therapeutic Potential of the Pim-1 Kinase in Colon Carcinoma
Weirauch, U., Beckmann, N., Thomas, M., Grünweller, A., Huber, K., Bracher, F., Hartmann, R. K., & Aigner, A. M. (2013) · Neoplasia · doi:10.1593/neo.13172 · Cited by 96
PIM Kinase Inhibitor AZD1208 for Treatment of MYC-Driven Prostate Cancer
Kirschner, A. N., Wang, J., van der Meer, R., Anderson, P. D., Coronel, O. E. F., Kushner, M. H., Everett, J. H., Hameed, O. M., Keeton, E. K., Ahdesmaki, M. J., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju407 · Cited by 96
Yang, F., Wang, F., Liu, Y., Wang, S., Li, X., Huang, Y., Xia, Y., & Cao, C. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.10.034 · Cited by 95
Wang, L., Xiang, S., Williams, K. A., Dong, H., Bai, W., Nicosia, S. V., Khochbin, S., Bepler, G., & Zhang, X. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044265 · Cited by 90
MicroRNA-486-5p targeting PIM-1 suppresses cell proliferation in breast cancer cells
Zhang, G., Liu, Z., Cui, G., Wang, X., & Yang, Z. (2014) · Tumor Biology · doi:10.1007/s13277-014-2412-0 · Cited by 88
Cao, J., Lv, W., Wang, L., Xu, J., Yuan, P., Huang, S., He, Z., & Hu, J. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0788-2 · Cited by 86
Lee, H., Tsai, A.-C., Chen, M.-C., Shen, P.-J., Cheng, Y.-C., Kuo, C., Pan, S., Liu, Y.-M., Liu, J.-F., Yeh, T., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401899x · Cited by 85
Pim1 kinase is required to maintain tumorigenicity in MYC-expressing prostate cancer cells
Wang, J., Anderson, P. D., Luo, W., Gius, D. R., Roh, M., & Abdulkadir, S. A. (2011) · Oncogene · doi:10.1038/onc.2011.371 · Cited by 84
Nakano, H., Saito, N., Parker, L. J., Tada, Y., Abe, M., Tsuganezawa, K., Yokoyama, S., Tanaka, A., Kojima, H., Okabe, T., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3001289 · Cited by 84
The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer
Zhou, Y., Shen, J. K., Hornicek, F. J., Kan, Q., & Duan, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.8519 · Cited by 84
Zic2 promotes tumor growth and metastasis via PAK4 in hepatocellular carcinoma
Lu, S.-X., Zhang, C. Z., Luo, R.-Z., Wang, C., Liu, L.-L., Fu, J., Zhang, L., Wang, H., Xie, D., & Yun, J. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.05.018 · Cited by 84
Self-citationHe, L., Xu, H., Chen, M., Xian, Z.-R., Wen, X.-F., Chen, M.-N., Wu, J., HUANG, W.-H., Wu, J., & Zhang, G. (2016) · Oncotarget · doi:10.18632/oncotarget.7466 · Cited by 82
Deng, D., Wang, L., Chen, Y., Li, B., Xue, L., Shao, N., Wang, Q., Xia, X., Yang, Y., & Zhi, F. (2016) · Cancer Science · doi:10.1111/cas.12946 · Cited by 82
A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas
Lwin, T., Zhao, X., Cheng, F., Zhang, X., Huang, A., Shah, B. D., Zhang, Y., Moscinski, L. C., Choi, Y. S., Kozikowski, A. P., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64210 · Cited by 79
Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells
Liu, J., Gu, J., Feng, Z., Yang, Y., Zhu, N., Lu, W., & Qi, F. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-015-0753-0 · Cited by 79
Ikeda, Y., Park, J.-H., Miyamoto, T., Takamatsu, N., Kato, T., Akiko, I., Okabe, S., Imai, Y., Fujiwara, K., Nakamura, Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0207 · Cited by 79
PIM1 regulates glycolysis and promotes tumor progression in hepatocellular carcinoma
Leung, C. O. N., Wong, C. C., Fan, D. N.-Y., Kai, A. K., Tung, E. K. K., Xu, M., Ng, I. O., & Lo, R. C. (2015) · Oncotarget · doi:10.18632/oncotarget.3534 · Cited by 78
HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma
Wang, Z., TANG, F., Hu, P., Wang, Y., Gong, J., Sun, S., & Xie, C. (2016) · Oncology Reports · doi:10.3892/or.2016.4811 · Cited by 71
Xu, D., Allsop, S. A., Witherspoon, S. M., Snider, J. L., Yeh, J. J., Fiordalisi, J. J., White, C. D. B., Williams, D., Cox, A. D., & Baines, A. T. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr007 · Cited by 70
Nguyen, A. N., Stebbins, E. G., Henson, M., O’Young, G., Choi, S. J., Quon, D. H., Damm, D., Reddy, M., Ma, J. Y., Haghnazari, E., et al. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.02.026 · Cited by 67
Blanco‐Aparicio, C., Collazo, A., Oyarzábal, J., Martínez-Leal, J. F., Albarán, M. I., Ramos-Lima, F., Pequeño, B., Ajenjo, N., Becerra, M., Alfonso, P., et al. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.09.016 · Cited by 67
Gururajan, R., Lahti, J. M., Grenet, J. A., Easton, J. B., Gruber, I., Ambros, P. F., & Kidd, V. J. (1998) · Genome Research · doi:10.1101/gr.8.9.929 · Cited by 67
Zhang, M., Liu, T., Sun, H., Weng, W., Zhang, Q., Liu, C., Yang, H., & Sheng, W. (2018) · Cancer Science · doi:10.1111/cas.13562 · Cited by 67
A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth
Kaliszczak, M., Trousil, S., Åberg, O., Perumal, M., Nguyen, Q.-D., & Aboagye, E. O. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.576 · Cited by 66
Li, S., Wang, Z., Mi, X., Liu, L., & Tan, Y. Q. (2015) · IUBMB Life · doi:10.1002/iub.1433 · Cited by 65
Self-citationJoshi, A. D., Botham, R. C., Schlein, L. J., Roth, H. S., Mangraviti, A., Borodovsky, A., Tyler, B., Joslyn, S. K., Looper, J., Podell, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19085 · Cited by 65
Song, Y. W., Lim, Y., & Cho, S. K. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.02.003 · Cited by 63
Seidel, C., Schnekenburger, M., Mazumder, A., Teiten, M.-H., Kirsch, G., Dicato, M. A., & Diederich, M. F. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.11.005 · Cited by 62
Constitutive activation of Pim1 kinase is a therapeutic target for adult T-cell leukemia
Bellon, M., Lü, L., & Nicot, C. (2016) · Blood · doi:10.1182/blood-2015-11-685032 · Cited by 62
Vishchuk, O. S., Sun, H., Wang, Z., Ermakova, S. P., Xiao, J., Lu, T., Xue, P., Николаевна, З. Т., Xiong, H., Shao, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7708 · Cited by 61
Zeng, B., Shi, W., & Tan, G. (2018) · BMC Cancer · doi:10.1186/s12885-017-3949-2 · Cited by 61
Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells
Aldana-Masangkay, G. I., Rodríguez-González, A., Lin, T. L., Ikeda, A. K., Hsieh, Y., Kim, Y., Lomenick, B., Okemoto, K., Landaw, E. M., Wang, D., et al. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.570821 · Cited by 60
PBK/TOPK mediates geranylgeranylation signaling for breast cancer cell proliferation
Dou, X., Wei, J., Sun, A., Shao, G., Childress, C., Yang, W., & Lin, Q. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0178-0 · Cited by 60
Putzbach, W., Gao, Q. Q., Patel, M., van Dongen, S., Haluck-Kangas, A., Sarshad, A. A., Bartom, E. T., Kim, K. A., Scholtens, D. M., Hafner, M., et al. (2017) · eLife · doi:10.7554/elife.29702 · Cited by 59
HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers
Putcha, P., Yu, J., Barrueco, R. R., Saucedo-Cuevas, L. P., Villagrasa, P., Murga-Penas, E., Quayle, S. N., Yang, M., Castro, V., Llobet‐Navàs, D., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0658-0 · Cited by 58
Zhao, B., Liu, L., Mao, J., Zhang, Z., Wang, Q., & Li, Q. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0348-9 · Cited by 58
Self-citationHDAC6 as a target for antileukemic drugs in acute myeloid leukemia
Hackanson, B. W., Rimmele, D. L., Benkißer-Petersen, M., Abdelkarim, M., Fliegauf, M., Jung, M., & Lübbert, M. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.02.026 · Cited by 57
Lei, B., Qi, W., Zhao, Y., Li, Y., Liu, S., Xu, X., Chen, Z., Wan, L., & Shen, H. (2014) · Human Pathology · doi:10.1016/j.humpath.2014.07.026 · Cited by 57
HDAC6 Deacetylates HMGN2 to Regulate Stat5a Activity and Breast Cancer Growth
Medler, T. R., Craig, J. M., Fiorillo, A. A., Feeney, Y. B., Harrell, J. C., & Clevenger, C. V. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0109 · Cited by 56
Chuang, M., Wu, S.-T., Tang, S., Lai, X., Lai, H.-C., Hsu, K.-H., Sun, K., Sun, G.-H., Chang, S.-Y., Yü, D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073401 · Cited by 54
c-Myc and E2F1 drive PBK/TOPK expression in high-grade malignant lymphomas
Hu, F., Gartenhaus, R. B., Zhao, X. F., Fang, H., Minkove, S. J., Poss, D. E., & Rapoport, A. P. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.11.010 · Cited by 54
Cosenza, M., Civallero, M., Marcheselli, L., Sacchi, S., & Pozzi, S. (2017) · APOPTOSIS · doi:10.1007/s10495-017-1364-4 · Cited by 54
Histone deacetylase 6 promotes growth of glioblastoma through inhibition of SMAD2 signaling
Li, S., Liu, X., Chen, X., Zhang, L., & Wang, X. (2015) · Tumor Biology · doi:10.1007/s13277-015-3747-x · Cited by 53
Kim, J., Son, J. E., Jeong, H., Kim, D. J., Seo, S. G., Lee, E., Lim, T. G., Kim, J. R., Kimbung, Y. R., Chen, H., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3655 · Cited by 53
PBK/TOPK mediates promyelocyte proliferation via Nrf2-regulated cell cycle progression and apoptosis
LIU, Y., Liu, H., Huiqin, C., Song, B., ZHANG, W., & Zhang, W. (2015) · Oncology Reports · doi:10.3892/or.2015.4308 · Cited by 53
Pim1 kinase is upregulated in glioblastoma multiforme and mediates tumor cell survival
Herzog, S., Fink, M. A., Weitmann, K., Friedel, C., Hadlich, S., Langner, S., Kindermann, K., Holm, T., Böhm, A., Eskilsson, E., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou216 · Cited by 53
Derivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities
Roth, H. S., & Hergenrother, P. J. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666151127201829 · Cited by 51
Kaliszczak, M. A., van Hechanova, E., Li, Y., Al-Sadah, H. A., Parzych, K., Auner, H. W., & Aboagye, E. O. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0232-5 · Cited by 51
Wang, F., Wang, L., Zhao, Y., Li, Y., Ping, G.-F., Shu Dong, X. I. A. O., Chen, K., Zhu, W., Gong, P., Yang, J., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.06.015 · Cited by 50
Novel selective TOPK inhibitor SKLB-C05 inhibits colorectal carcinoma growth and metastasis
Gao, T., Hu, Q., Hu, X., Lei, Q., Feng, Z., Yu, X. Y., Peng, C., Song, X., He, H., Xu, Y. X., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.12.016 · Cited by 50
Bai, J., Lei, Y., An, G., & He, L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121247 · Cited by 49
PAK4 interacts with p85 alpha: implications for pancreatic cancer cell migration
King, H. A., Thillai, K., Whale, A. D., Arumugam, P., Eldaly, H., Kocher, H. M., & Wells, C. M. (2017) · Scientific Reports · doi:10.1038/srep42575 · Cited by 49
Zhang, I., Beus, M., Stochaj, U., Le, P. U., Zorc, B., Rajić, Z., Petrecca, K., & Maysinger, D. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0103-0 · Cited by 49
Stauffer, S., Zeng, Y., Zhou, J., Chen, X., Chen, Y., & Dong, J. (2017) · Cellular Signalling · doi:10.1016/j.cellsig.2017.08.001 · Cited by 48
Xu, J., Wang, P., Yang, H. J., Zhou, J., Li, Y., Li, X., Xue, W., Yu, C., Tian, Y., & Zhu, F. (2016) · BioMed Research International · doi:10.1155/2016/2509385 · Cited by 47
Genetic disruption of oncogenic Kras sensitizes lung cancer cells to Fas receptor-mediated apoptosis
Mou, H., Moore, J., Malonia, S. K., Li, Y., Ozata, D. M., Hough, S., Song, C.-Q., Smith, J. L., Fischer, A., Weng, Z., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620861114 · Cited by 46
Clinical and therapeutic relevance of PIM1 kinase in gastric cancer
Yan, B., Yau, E. X., Samanta, S., Ong, C. W., Yong, K. J., Ng, L. K., Bhattacharya, B., Lim, K. H., Soong, R., Yeoh, K. G., et al. (2011) · Gastric Cancer · doi:10.1007/s10120-011-0097-2 · Cited by 46
Limoge, M., Safina, A. F., Truskinovsky, A. M., Aljahdali, I. A. M., Zonneville, J., Gruevski, A., Arteaga, C. L., & Bakin, A. V. (2017) · Oncotarget · doi:10.18632/oncotarget.18755 · Cited by 46
ADA-07 Suppresses Solar Ultraviolet–Induced Skin Carcinogenesis by Directly Inhibiting TOPK
Gao, G., Zhang, T., Wang, Q., Reddy, K., Chen, H., Yao, K., Wang, K., Roh, E., Zykova, T. A., Ma, W., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0212 · Cited by 45
Pim1 promotes cell proliferation and regulates glycolysis via interaction with MYC in ovarian cancer
Wu, Y., Deng, Y., Zhu, J. W., Duan, Y., Weng, W., & Wu, X. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s180520 · Cited by 44
Castillo, J., Knol, J. C., Korver, C. M., Piersma, S. R., Pham, T. V., Haas, R. R. D. G., van Pelt, A. M. M., Jiménez, C. R., & Jansen, B. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra118.001278 · Cited by 44
Differential Effects of Procaspase-3 Activating Compounds in the Induction of Cancer Cell Death
West-Szymanski, D. C., Qin, Y., Peterson, Q. P., Thomas, D., Palchaudhuri, R., Morrison, K. C., Lucas, P. W., Palmer, A. E., Fan, T. M., & Hergenrother, P. J. (2012) · Molecular Pharmaceutics · doi:10.1021/mp200673n · Cited by 43
Dong, J., Zheng, N., Wang, X., Tang, C. C., Yan, P., Zhou, H., & Huang, J. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.03.026 · Cited by 43
Ma, J., Chen, D., Lu, K., Wang, L., Han, X., Zhao, Y., & Gong, P. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.08.058 · Cited by 42
Vanderkerken, K., Medicherla, S., Coulton, L. A., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4361 · Cited by 42
Fu, X., Zhang, X., Yang, H., Xu, X., Hu, Z.-L., Yan, J., Zheng, X., Wei, R.-R., Zhang, Z., Tang, S.-R., et al. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0108-5 · Cited by 42
Morishita, D., Takami, M., Yoshikawa, S., Katayama, R., Sato, S., Kukimoto‐Niino, M., Umehara, T., Shirouzu, M., Sekimizu, K., Yokoyama, S., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.092452 · Cited by 40
Botham, R. C., Fan, T. M., Im, I., Borst, L. B., Dirikolu, L., & Hergenrother, P. J. (2014) · Journal of the American Chemical Society · doi:10.1021/ja4124303 · Cited by 40
p38α Is Required for Ovarian Cancer Cell Metabolism and Survival
Matrone, A., Grossi, V., Chiacchiera, F., Fina, E., Cappellari, M., Caringella, A. M., Naro, E. D., Loverro, G., & Simone, C. (2010) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181c8ca12 · Cited by 40
Xiao, J., Duan, Q., Wang, Z., Yan, W., Sun, H., Xue, P., Fan, X., Zeng, X., Chen, J., Shao, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8231 · Cited by 40
Heterogeneous Cell Types in Single-cell-derived Clones of MCF7 and MDA-MB-231 Cells
Khan, G. N., Kim, E., Shin, T. S., & Lee, S. H. (2017) · Anticancer Research · doi:10.21873/anticanres.11572 · Cited by 40
Song, X., Yin, S., Zhang, E., Fan, L., Ye, M., Zhang, Y., & Hu, H. (2016) · Oncotarget · doi:10.18632/oncotarget.11610 · Cited by 39
Li, N., Lopez, M. A., Linares, M., Kumar, S., Oliva, S., Martínez‐López, J., Xu, L., Xu, Y., Perini, T., Senapedis, W. T., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1776 · Cited by 39
HDAC6 inhibition suppresses chondrosarcoma by restoring the expression of primary cilia
Xiang, W., Guo, F., Cheng, W., Zhang, J., Huang, J., Wang, R., Ma, Z., & Xu, K. L. (2017) · Oncology Reports · doi:10.3892/or.2017.5694 · Cited by 37
Abdelhafez, O. M., Ahmed, E. Y., Latif, N. A. A., Arafa, R. K., Elmageed, Z. Y. A., & Ali, H. I. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.02.027 · Cited by 37
Histone Deacetylase 6 Regulates Estrogen Receptor α in Uterine Leiomyoma
Wei, L., Torng, P., Hsiao, S., Jeng, Y., Chen, M., & Chen, C. (2011) · Reproductive Sciences · doi:10.1177/1933719111398147 · Cited by 36
Park, J., Inoue, H., Kato, T., Zewde, M. G., Miyamoto, T., Matsuo, Y., Salgia, R., & Nakamura, Y. (2017) · Cancer Science · doi:10.1111/cas.13160 · Cited by 36
Zhao, B., Liu, L., Mao, J., Zhang, Z., Wang, Q., & Li, Q. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03387-3 · Cited by 36
Self-citationTan, Y., Zhang, S., Zhu, H., Chu, Y., Zhou, H., Liu, D., & Huo, J. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2018.11.48 · Cited by 35
Park, S. J., Kim, J. K., Bae, H. J., Eun, J. W., Shen, Q., Kim, H. S., Shin, W. C., Yang, H. D., Lee, E. K., You, J. S., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.07.041 · Cited by 35
Small molecules not direct activators of caspases
Denault, J., Drąg, M., Salvesen, G. S., et al. (2007) · Nature Chemical Biology · doi:10.1038/nchembio0907-519 · Cited by 35
Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance
Gurden, M. D. J., Westwood, I. M., Faisal, A., Naud, S., Cheung, K.-M. J., McAndrew, C., Wood, A., Schmitt, J., Boxall, K. J., Mak, G. W.-Y., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3272 · Cited by 34
Pim-1 acts as an oncogene in human salivary gland adenoid cystic carcinoma
Zhu, X., Xu, J., Hu, S., Feng, J., Jiang, L., Hou, X., Cao, J., Han, J., Ling, Z., & Ge, M. (2014) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-014-0114-5 · Cited by 33
Zhang, Y., Wang, X., Qin, X., Wang, X., Liu, F., White, E., & Zheng, X. F. S. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.11.031 · Cited by 33
The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas
Peh, J., Fan, T. M., Wycislo, K. L., Roth, H. S., & Hergenrother, P. J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0025 · Cited by 33
Smedt, R. D., Peirs, S., Morscio, J., Matthijssens, F., Roels, J., Reunes, L., Lintermans, B., Goossens, S., Lammens, T., Roy, N. V., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.199257 · Cited by 33
Planchard, D., Camara‐Clayette, V., Dorvault, N., Soria, J., & Fouret, P. J. (2012) · Cancer · doi:10.1002/cncr.27510 · Cited by 32
PIM kinases as therapeutic targets against advanced melanoma
Shannan, B., Watters, A. K., Chen, Q., Mollin, S., Dörr, M., Meggers, E., Xu, X., Gimotty, P. A., Perego, M., Li, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10703 · Cited by 30
Medicherla, S., Reddy, M., Jing, Y., Navas, T. A., Li, L., Nguyen, A. N., Kerr, I., Hanjarappa, N., Protter, A. A., & Higgins, L. S. (2008) · PubMed · Cited by 28
Cited by
Oughtred, R., Rust, J., Chang, C., Breitkreutz, B., Stark, C., Willems, A., Boucher, L., Leung, G., Kolas, N., Zhang, F., et al. (2021) · Protein Science · doi:10.1002/pro.3978 · Cited by 1,858
“Conversely, screens that enrich for sgRNA-generated indels that cause resistance to a particular drug, 54 – 56 toxin, 57 pathogen, 58,59 or adverse environmental condition 60 are termed positive selection screens (Figure 3).”
BackgroundWhy 90% of clinical drug development fails and how to improve it?
Sun, D., Gao, W., Hu, H., & Zhou, S. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.002 · Cited by 1,763
Radiopharmaceutical therapy in cancer: clinical advances and challenges
Sgouros, G., Bodei, L., McDevitt, M. R., & Nedrow, J. R. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0073-9 · Cited by 963
Seyhan, A. A. (2019) · Translational Medicine Communications · doi:10.1186/s41231-019-0050-7 · Cited by 713
Zhou, Y., Zhang, Y., Lian, X., Li, F., Wang, C., Zhu, F., Qiu, Y., & Chen, Y. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab953 · Cited by 665
Metadata
- Authors
- Lin, A., Giuliano, C. J., Palladino, A., John, K. M., Abramowicz, C., Yuan, M. L., Sausville, E. L., Lukow, D. A., Liu, L., Chait, A. R., Galluzzo, Z. C., Tucker, C., & Sheltzer, J. M.
- Venue
- Science Translational Medicine
- Published
- 2019-09-11
- Volume
- 11
- Issue
- 509
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2973039076
- Cited by
- 754
- References
- 227
- FWCI
- 49.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.